Catalyst Financial Partners’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.26M Buy
25,620
+1,551
+6% +$361K 0.74% 23
2025
Q4
$4.98M Buy
24,069
+2,182
+10% +$431K 0.56% 27
2025
Q3
$4.06M Buy
21,887
+493
+2% +$84.5K 0.49% 26
2025
Q2
$3.27M Sell
21,394
-6,759
-24% -$1.04M 0.36% 30
2025
Q1
$4.67M Sell
28,153
-388
-1% -$60.7K 0.86% 21
2024
Q4
$4.13M Sell
28,541
-1,734
-6% -$269K 0.78% 23
2024
Q3
$4.91M Sell
30,275
-2,033
-6% -$324K 0.96% 15
2024
Q2
$4.72M Sell
32,308
-5,025
-13% -$747K 1.04% 16
2024
Q1
$5.4M Sell
37,333
-1,582
-4% -$252K 1.39% 15
2023
Q4
$6.1M Sell
38,915
-5,097
-12% -$782K 1.72% 12
2023
Q3
$6.85M Sell
44,012
-5,099
-10% -$841K 2.21% 11
2023
Q2
$8.13M Buy
49,111
+36,032
+275% +$5.82M 2.9% 9
2023
Q1
$2.03M Buy
13,079
+2,049
+19% +$331K 0.87% 22
2022
Q4
$1.95M Buy
+11,030
New +$1.9M 1% 18

Other funds holding JNJ

Catalyst Financial Partners's JNJ Position: Q1 2026 in Review

Catalyst Financial Partners increased its Johnson & Johnson (JNJ) stake by 6.4% in Q1 2026, buying an estimated $361K and bringing the position to 25,620 shares worth $6.26M. The position accounts for 0.74% of the portfolio, ranked #23.

Catalyst Financial Partners first reported a position in JNJ in Q4 2022 and has held it in 14 quarters since. The position peaked at $8.13M in Q2 2023. 4,613 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

  • Catalyst Financial Partners held 25,620 shares of Johnson & Johnson worth $6.26M as of Q1 2026.
  • Catalyst Financial Partners bought 1,551 Johnson & Johnson shares in Q1 2026, an estimated $361K.
  • Johnson & Johnson made up 0.74% of Catalyst Financial Partners's portfolio in Q1 2026, its #23 holding.
  • Catalyst Financial Partners first reported a position in Johnson & Johnson in Q4 2022 and has held it in 14 quarters since.
  • Catalyst Financial Partners's Johnson & Johnson position peaked at $8.13M in Q2 2023.
  • 4,613 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on Catalyst Financial Partners's 13F filing for Q1 2026, filed 12 May 2026.